Log in to save to my catalogue

IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing ant...

IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing ant...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_03031762v1

IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies

About this item

Full title

IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies

Publisher

New York: Nature Publishing Group US

Journal title

Nature Medicine, 2020-07, Vol.26 (7), p.1096-1101

Language

English

Formats

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

Neutralizing antibodies to adeno-associated virus (AAV) vectors are highly prevalent in humans
1
,
2
, and block liver transduction
3

5
and vector readministration
6
; thus, they represent a major limitation to in vivo gene therapy. Strategies aimed at overcoming anti-AAV antibodies are being studied
7
, which...

Alternative Titles

Full title

IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_hal_primary_oai_HAL_hal_03031762v1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_03031762v1

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X,1744-7933

DOI

10.1038/s41591-020-0911-7

How to access this item